StudyRareStudyRare
Log in to add personal notes on this page.

A 35-year-old woman presents with recurrent kidney stones and is found to have elevated calcium and PTH. Further workup reveals a prolactinoma on brain MRI. Her father had a pancreatic neuroendocrine tumor resected at age 40.

AD; MEN1 (menin, tumor suppressor on chromosome 11q13); loss of function, with somatic loss of the second copy in each tumor

  • ~10% de novo
  • High penetrance (more than 50% by age 20, 95% by age 40)
  • Loss of heterozygosity (LOH) at tumor sites

Menin is a nuclear protein that restrains cell proliferation. It binds transcription factors such as JunD, NF-kB, PPAR-gamma, and the vitamin D receptor; works with histone-modifying enzymes and the polycomb group to control which promoters transcription factors can reach; binds gene promoters directly; and regulates TGF-beta and Wnt/beta-catenin signaling. It also has tissue-specific roles in DNA replication and repair.

The syndrome follows the two-hit model. Every cell carries one inactive germline copy, and a tumor arises in a parathyroid, pituitary, or pancreatic or duodenal endocrine cell when the remaining copy is lost by a somatic variant or deletion. The same double loss of MEN1 is found in 15% to 20% of sporadic parathyroid adenomas, and loss of heterozygosity at 11q13 in 5% to 50% of sporadic endocrine tumors.

No direct genotype-phenotype correlation exists, and variants occur along the whole coding region. The one known cluster is the Burin variant (p.Arg460Ter) in families from Newfoundland and Mauritius, with more prolactinomas and fewer gastrinomas than usual. Variants affecting the JunD-interacting domain were linked to a twofold higher risk of death in one study.

The 3 Ps:

  • Parathyroid adenomas (>90%): most common and usually earliest manifestation; primary hyperparathyroidism
  • Pituitary adenomas (~40%): prolactinoma most common; also GH-secreting, ACTH-secreting
  • Pancreatic neuroendocrine tumors (~60%): gastrinoma (Zollinger-Ellison syndrome), insulinoma, non-functioning

Other tumors:

  • Adrenal cortical tumors (~25%)
  • Facial angiofibromas, collagenomas
  • Thymic/bronchial carcinoids
  • Genetic testing for MEN1 pathogenic variants
  • Clinical diagnosis: ≥2 of the 3 Ps, or 1 of the 3 Ps plus a first-degree relative with MEN1
  • Biochemical screening starting by age 8 in at-risk family members
  • Annual calcium/PTH, prolactin, fasting glucose/insulin, gastrin
  • Periodic imaging (MRI pituitary, CT/MRI abdomen)
  • Parathyroidectomy for hyperparathyroidism
  • Tumor-specific surgical and medical management

3 Ps of MEN1: Parathyroid, Pituitary, Pancreas

Reference Links